

VPA10983/044/003

**Cefaseptin 750 mg tablets for dogs**

<b>Variation</b>	<b>Summary</b>	<b>Date</b>
Vet - B28 b)	VNRA - Vet - B28 b) - b) Addition of a new specification parameter to the specification with its corresponding test method - B28 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an excipient —addition of a new specification parameter to the specification with its corresponding test method	04/03/25
Vet - B3 m)	VNRA - Vet - B3 m) - m) Deletion of a non-significant specification parameter (excipient) - B3 m) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) in the specification parameters or limits of an excipient	04/03/25
Vet - B12 b)	VNRA - Vet - B12 b) - b) Minor changes to an approved test procedure (starting material, excipient) - B12 b) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient	04/03/25
Vet - B28 a)	VNRA - Vet - B28 a) - a) Tightening of specification limits - B28 a) Changes to the quality part of the dossier: Change in the specification parameters or limits of an excipient — tightening of specification limits	04/03/25
Vet - B43	VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	03/04/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	16/06/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	16/06/23